A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessThe DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
Abstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 6×
“estimated that there will be over 700 million T2D patients worldwide.(1,62) However, as highlighted in”
InfluentialBiochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Items 401–442 of 442
Future prospective and challenges in neurobiology of type 2 diabetes
Dubey, M., Ranjan, S., & Kumar, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-32848-0.00016-9
Emerging therapeutic approaches in neurobiology of type 2 diabetes
Kumar, U., Garg, S., Shrivastav, A., Sharma, B., Arora, B., Sahu, B., & Gupta, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-32848-0.00023-6
Yoo, J. H., Lee, Y., Jun, J. E., Lee, K. N., & Han, K. (2026) · BMC Public Health · doi:10.1186/s12889-026-26986-1
“Owing to its high prevalence and projected increase in prevalence [4], it is anticipated that the financial costs associated with T2D would rise further.”
Beura, S., Das, A. K., & Ghosh, A. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70192
Role play of regulatory T cells and resolvins in type 2 diabetes
Krishnan, S., Mahadevan, S., Sharma, H. P., Das, U. N., & Kuppan, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1748000
Mental Health Status and Associated Factors Among Type 2 Diabetic Patients in Cameroon
Esembeson, M., Endam, T. S., & Tendongfor, N. (2026) · Central African Journal of Public Health · doi:10.11648/j.cajph.20261202.13
Kapase, P., Jadhav, K. R., & Sanap, D. P. (2026) · Progress in Nanoscience and Nanotechnology · doi:10.2174/0131173640453481260127100936
Başeğmez, M., Eryavuz, A. M., Avşar, M. T., Atik, H. D., Demirel, H. H., Durmuş, İ., & Eryavuz, A. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71699
Metabolic environment and epigenetic programming of the early embryo in rabbit
y Rada, R. V. (2022) · theses.fr (ABES) · doi:10.70675/536319d0z3a53z4da0z808cz9ab1c3f5ac7a
Saab, C., Mansour, A. A., Rahmah, A. M., Al-Attar, D. M. R. A., Alrubaye, H. F., Alidrisi, H. A., Nwayyir, H. A., Khudhair, M. S., Ahmed, M. J., AL-Ibrahimi, S. M., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01861-9
Cahyaningsih, I., Rokhman, M. R., Maziyyah, N., Mubarik, S., Denig, P., & Taxis, K. (2026) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2026.112684
Vitamin D deficiency and depression in diabetes mellitus: A systematic review and meta-analysis
Hernández-López, M., Grande‐Alonso, M., Aguado-Henche, S., Ramírez-Carracedo, R., Sebastián-Martín, A., & Moreno‐Gómez‐Toledano, R. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501743
Systematic review and meta-analysis on depression burden among Type 2 diabetes patients in India
Halder, P., Debnath, A., Achary, T., Mondal, A., Dhandapani, G., Mandal, I., Saha, S., Nongkynrih, B., & Thakur, J. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02160-w · Cited by 1
“Globally, type 2 diabetes (T2DM), a chronic metabolic disease marked by insulin resistance and hyperglycaemia, has become a pandemic [1]. he diabetes prevalence anticipated to increase from 537 million in 2021 to 783 million by 2045, T2DM accounting for the majority of this increase.”
Kim, D.-J., Leem, J., Lee, Y. J., Ha, I.-H., & Lee, Y.-S. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14657-1
“Beyond its well-known microvascular and macrovascular complications, T2DM is increasingly recognized as a condition that adversely affects musculoskeletal health [1, 2].”
Raghunathan, R., Pawase, P. A., Pathare, A. M., Singh, D., Chandola, G., Mudgal, S., Bashir, O., & Ahmad, M. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101221
Ozkan, S., & Koçar, İ. Ç. (2026) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1964544
Roh, W.-L., Shin, W., Yoo, H., Ahn, K. H., Lee, Y., & Kim, A. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-01014-0
“…resistance and β-cell dysfunction injures the kidneys, eyes, nerves, and heart, and contributes to poor wound healing, infections, neuropathy, impotence, and neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease [2], and may progressively contribute to reduced life expectancy [3].”
Health behavior changes after type 2 diabetes diagnosis: a 16-year longitudinal cohort study
Ro, H. J., & Ahn, S. V. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113367
Ojha, M., Yadav, A., Behera, P., Jha, N. S., Mishra, M., & Jha, S. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153153
Zahedi, M., Hamidi, A. K., Jafari‐Raddani, F., Shirkouhi, M. A., Amoli, M. M., & Razi, F. (2026) · Research Square · doi:10.21203/rs.3.rs-10040418/v1
Meenu, Aqil, M., Haque, S. E. U., Akhtar, M., Mujeeb, M., Zaidi, Z., Ismail, M. V., & Najmi, A. K. (2026) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x261463364
Mohammed, S. A., & Ismael, D. H. (2026) · Journal of Nutritional Science · doi:10.1017/jns.2026.10133
Jha, A., Abinaya, R., Ojha, R., Paul, M. K., Sivakumar, M. B., Rao, S. R., & Santra, T. S. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1865992 · Cited by 1
“Globally, approximately 382 million individuals are affected by diabetes, and the continued rise in prevalence indicates that diabetes is likely to pose a major global pandemic challenge in the coming decades (Reed et al., 2021).”
Rasmussen, J. L. P., Gram-Kampmann, E.-M., Stidsen, J. V., Hansen, C. D., Krag, A. A., Olsen, M. H., Beck‐Nielsen, H., Handberg, A., & Højlund, K. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101400 · Cited by 1
Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development
Sureka, C., Muniyandi, V., Geddawy, A., Ramesh, T., Murugesan, A., & Kandhavelu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1916297
Turkar, M. K., Ahirwar, R., Sahu, R., Bhadane, R. N., Jain, S., & Jain, D. (2026) · ACS Omega · doi:10.1021/acsomega.5c13626
Sawant, H., Sun, B., Li, Y., Zhu, C., Meyer, R., Sodhi, K., Borthakur, A., & Bihl, J. C. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090896
“The prevalence of T2DM continues to rise worldwide as a modern-world lifestyle is increasingly being adopted [1,2].”
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
“Excess body weight is common in T2DM and is associated with increased cardiometabolic risk, while weight reduction can improve glycaemic control and related risk factors 29,30 .”
From metabolites to membrane vesicles: Unifying gut microbial signals in obesity, t2dm, and MASLD
Barathan, M., Venkatraman, G., & Abdul‐Rahman, P. S. (2026) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-026-05249-6 · Cited by 1
“Their occurrence is mainly attributable to urbanization, growing elderly populations, sedentary behaviors, and consumption of energy-rich diets (Moore et al. 2026; Reed et al. 2026).”
Preservation of Nociceptor Intraepidermal Nerve Fibres in Diabetic Neuropathic Pain
Lione, L. A., Hardowar, L. D., Lanigan, M. T., Bates, J., Whines, W. T. B., Jones, H., & Hulse, R. P. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/4561974
“These features are especially relevant given that over 90% of diabetic patients have Type 2 diabetes [15].”
Diabetes Mellitus and Antidiabetic Medications
Mirrakhimov, A. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-29397-8_113
van Staden, C., Greyling, C., Jacobs, J., & Milne, M. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4797
Gana, A. A., Abdulkadir, Z., Damagun, F. M., Ogunyele, T. T., Olawumi, A. L., Iroezindu, G. U., Suleiman, A. K., Kwaku, A. A., Benjamin, T. A., Michael, G. C., et al. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02592-5
Konstantopoulou, S. M., Foscolou, A., Papazafiropoulou, A. K., Makris, A. P., Leftaki, A. D., Panagiotopoulos, G., Gioxari, A., Lampropoulou, D. I., Detopoulou, P., Panoutsopoulos, G. I., et al. (2026) · Nutrients · doi:10.3390/nu18193130
The Klf7/Glut2/Ins2 Axis Regulates Glucose Homeostasis
Yang, C., Liu, H., Wang, C., Zhu, F., Guo, M., & Tian, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198553
“Dysregulation of glucose homeostasis is a pivotal factor in the development and progression of diabetes mellitus, in which pancreatic β -cell dysfunction and insulin resistance converge to drive persistent hyperglycaemia [4–6].”
Chellappan, D., & Rajaguru, H. (2026) · Control Instrumentation System Conference (CISCON) · doi:10.1109/ciscon71603.2026.11709336
Bucciarelli, L., Lunati, M. E., Berra, C., Cerutti, N., Conti, A., Ghelardi, R., Girelli, A., Morpurgo, P. S., Rossi, A., Scaranna, C., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02798-y
The immunometabolic basis of chronic metabolic diseases
Sangineto, M., Ciarnelli, M., Bianco, R., Savino, G., Girolamo, G. D., Gioia, G. D., Colangelo, T., & Serviddio, G. (2026) · Trends Open · doi:10.1016/j.treopn.2026.09.003
Lehmann, M., Hò, G. T., Augstein, P., Baranowska-Dell, M., Dähnrich, C., Deerberg, A., Saschenbrecker, S., Kerner, W., Komorowski, L., Kühnl, A., et al. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.122866
Zhong, X., Qiuna, W., Cheng, Q., Weng, M., Wang, S., Chen, H., & Ruan, Y. (2026) · Diabetologia · doi:10.1007/s00125-026-06885-1
Sawant, V. N., & Sawant, S. (2026) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v19i3.4032
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.